The global oligonucleotides market is experiencing significant growth, driven by increasing applications in genetic research, diagnostics, and therapeutics. Oligonucleotides, short DNA or RNA fragments, are pivotal in gene therapies, drug discovery, and molecular diagnostics, fueling demand across pharmaceutical and biotechnology industries.
Additionally, the rising prevalence of genetic disorders, cancer, and chronic diseases is propelling the need for targeted treatments and diagnostics. The growing adoption of CRISPR technology, RNA-based therapies, and advancements in gene editing techniques are expected to further expand the market.
Key players in the industry are focusing on enhancing production capabilities and expanding product offerings. The ongoing development of new oligonucleotide drugs, such as antisense oligonucleotides and small interfering RNA (siRNA), for treating various diseases is further boosting market potential.
The term "oligonucleotide" originates from the Greek word *oligo*, meaning "small" or "few." These molecules are short strands of DNA or RNA, typically consisting of 13 to 25 nucleotide bases. The base length of oligonucleotides market is often referred to as "mer," derived from the Greek word for "part."
Oligonucleotides market are short, synthetic sequences of nucleic acids (DNA or RNA) that play a critical role in a wide range of molecular biology techniques, including PCR (Polymerase Chain Reaction), gene sequencing, and gene editing. These versatile molecules are used in drug discovery, cancer therapy, genetic testing, and more recently in RNA-based treatments such as mRNA vaccines.
| Attribute | Detail |
|---|---|
| Drivers |
|
Oligonucleotides market are synthesized using solid-phase chemical techniques and can be customized to meet specific client requirements. Their primary function is to hybridize with complementary nucleotide sequences.
These versatile molecules play a crucial role in various molecular biology applications, including polymerase chain reaction (PCR) as probes, DNA microarray techniques, Southern blot assays, Fluorescent in Situ Hybridization (FISH), and Allele-Specific Oligonucleotide (ASO) analysis.
The growing number of FDA-approved oligonucleotide drugs is a significant driver for the oligonucleotide market, reflecting advancements in biotechnology and precision medicine. Oligonucleotides, which are short sequences of nucleotides, play a crucial role in gene therapy, antisense therapy, and RNA interference (RNAi), enabling targeted treatments for various diseases, including genetic disorders, cancers, and viral infections.
For instance In 2023, FDA approved four ONTs ; AstraZeneca-Ionis’ Wainua (eplontersen), Novo Nordisk owned Dicerna Pharmaceuticals’ Rivfloza (nedosiran), Biogen-Ionis’ Qalsody (tofersen) and Iveric Bio’s Izervay (avacincaptad pegol).
Additionally, the increasing approval of these drugs highlights the expanding therapeutic applications of oligonucleotides. For instance, the FDA has approved several antisense oligonucleotides market that target specific genes to modify disease processes, offering new hope for patients with previously untreatable conditions.
This trend not only validates the therapeutic potential of oligonucleotides but also encourages further investment and research in the field. Moreover, the rise in chronic diseases and genetic disorders globally has created a growing demand for innovative treatment options.
As healthcare providers seek more effective therapies with fewer side effects, oligonucleotide drugs are increasingly viewed as viable alternatives to traditional small-molecule drugs and biologics. The support from regulatory agencies, coupled with the ongoing advancements in delivery mechanisms and oligonucleotide synthesis technologies, further enhances the attractiveness of this market.
A critical driver of the boosting market growth is the increasing investment in healthcare infrastructure, particularly in emerging economies. As countries such as India and China are expanding their healthcare systems, there is a growing need for advanced diagnostic tools that can provide accurate analytical results. Atomic spectroscopy techniques are essential for various applications within healthcare, including drug development, clinical diagnostics, and biomonitoring.
The pharmaceutical industry is witnessing a surge in research and development activities aimed at discovering new therapies. With an estimated 300 new medications expected to be introduced globally over the next few years, the demand for atomic spectroscopy in drug formulation analysis will rise correspondingly. These techniques help ensure that medications are free from harmful elemental impurities.
Additionally, as personalized medicine gains traction, the need for precise elemental analysis will further drive market growth. Investment in healthcare also extends to improving laboratory capabilities. Governments and private sectors are allocating funds toward upgrading laboratory equipment to enhance analytical accuracy. This shift not only supports better patient outcomes but also aligns with global health initiatives aimed at improving public health standards
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest oligonucleotides market analysis, North America held the largest share during 2023. Factors such as modern healthcare and medical infrastructure, major investments in research and development activities, and presence of multiple pharmaceutical and biotechnology companies in the region are anticipated to drive the market expansion. Several factors help North America to retain its leading position in this industry.
Moreover, growing focus on precision medicine and personalized therapies further accelerates the demand for oligonucleotides as treatments involving these agents impose site-specific modes of action against multifarious health conditions.
Furthermore, significant market players like Ionis Pharmaceuticals and Alnylam Pharmaceuticals drive further innovation and competition in the market. In conclusion, North America offers sophisticated research facilities, huge funding for biotechnology projects, and an extremely favorable atmosphere for trials, thus making it the leader in the oligonucleotide global market.
The Oligonucleotides industry is fragmented with the presence of a number of players. Emerging players in the oligonucleotides market include Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, Thermo Fisher Scientific, Merck, Microsynth, Nitto Avecia, Ribo Biotechnology, and STA Pharmaceutical/Wuxi STA, etc.
Key players have been have been profiled in the Oligonucleotides market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 3.7 Bn |
| Forecast Value in 2034 | More than US$ 13.1 Bn |
| CAGR | 11.9% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 3.4 Bn in 2023.
It is projected to reach more than US$ 13.1 Bn by the end of 2034.
Increasing demand for accurate analytical techniques and rising investment in healthcare infrastructure.
The CAGR is anticipated to be 11.9% from 2024 to 2034.
North America is expected to account for the largest share from 2024 to 2034.
Agilent Technologies, Ajinomoto Bio-Pharma Services, CordenPharma, Creative Biolabs, Ella Biotech, Eurofins Genomics, Future synthesis, Integrated DNA Technologies, Kaneka Eurogentec, Thermo Fisher Scientific, Merck, Microsynth, Nitto Avecia, Ribo Biotechnology, and STA Pharmaceutical/Wuxi STA, and Other Prominent Players.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Oligonucleotides Market
4. Market Overview
4.1. Introduction
4.1.1. Segmentation Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oligonucleotides Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. No. of Oligonucleotides being developed in world by Key Regions
5.2. List of top Oligonucleotides products
5.3. Pricing Analysis
5.4. Go-to-Market Strategy
5.5. Key Purchase Metrics for End-users
5.6. PESTEL Analysis
5.7. Key Industry Events
5.8. Porter's Five Forces Analysis
5.9. Regulatory Scenario by Key Countries/Regions
5.10. Product/Brand Analysis
5.11. Distributors Landscape
5.12. Technological Advancements
5.13. Fund Raise/Investment Scenario
5.14. Recommendations and Analyst View for the Market
6. Global Oligonucleotides Market Analysis and Forecasts, By Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2020-2034
6.3.1. Antisense Oligonucleotides
6.3.2. DNA
6.3.3. siRNA
6.3.4. Others (CpG Oligonucleotides)
6.4. Market Attractiveness By Type
7. Global Oligonucleotides Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2020-2034
7.3.1. Molecular Biology
7.3.2. Gene Therapy
7.3.3. Drug Development
7.3.4. Diagnostics
7.3.5. Others (Nanotechnology, Research studies etc.)
7.4. Market Attractiveness By Application
8. Global Oligonucleotides Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Pharma & Biopharma Companies
8.3.3. Diagnostic Laboratories
8.3.4. Biotechnology Companies
8.3.5. CROs and CMOs
8.3.6. Others (Academic Research Institutes, etc.)
8.4. Market Attractiveness By End-user
9. Global Oligonucleotides Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Oligonucleotides Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Type, 2020-2034
10.2.1. Antisense Oligonucleotides
10.2.2. DNA
10.2.3. siRNA
10.2.4. Others (CpG Oligonucleotides)
10.3. Market Value Forecast By Application, 2020-2034
10.3.1. Molecular Biology
10.3.2. Gene Therapy
10.3.3. Drug Development
10.3.4. Diagnostics
10.3.5. Others (Nanotechnology, Research studies etc.)
10.4. Market Value Forecast By End-user, 2020-2034
10.4.1. Hospitals
10.4.2. Pharma & Biopharma Companies
10.4.3. Diagnostic Laboratories
10.4.4. Biotechnology Companies
10.4.5. CROs and CMOs
10.4.6. Others (Academic Research Institutes, etc.)
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Oligonucleotides Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type, 2020-2034
11.2.1. Antisense Oligonucleotides
11.2.2. DNA
11.2.3. siRNA
11.2.4. Others (CpG Oligonucleotides)
11.3. Market Value Forecast By Application, 2020-2034
11.3.1. Molecular Biology
11.3.2. Gene Therapy
11.3.3. Drug Development
11.3.4. Diagnostics
11.3.5. Others (Nanotechnology, Research studies etc.)
11.4. Market Value Forecast By End-user, 2020-2034
11.4.1. Hospitals
11.4.2. Pharma & Biopharma Companies
11.4.3. Diagnostic Laboratories
11.4.4. Biotechnology Companies
11.4.5. CROs and CMOs
11.4.6. Others (Academic Research Institutes, etc.)
11.5. Market Value Forecast By Country/Sub-region, 2020-2034
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Oligonucleotides Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type, 2020-2034
12.2.1. Antisense Oligonucleotides
12.2.2. DNA
12.2.3. siRNA
12.2.4. Others (CpG Oligonucleotides)
12.3. Market Value Forecast By Application, 2020-2034
12.3.1. Molecular Biology
12.3.2. Gene Therapy
12.3.3. Drug Development
12.3.4. Diagnostics
12.3.5. Others (Nanotechnology, Research studies etc.)
12.4. Market Value Forecast By End-user, 2020-2034
12.4.1. Hospitals
12.4.2. Pharma & Biopharma Companies
12.4.3. Diagnostic Laboratories
12.4.4. Biotechnology Companies
12.4.5. CROs and CMOs
12.4.6. Others (Academic Research Institutes, etc.)
12.5. Market Value Forecast By Country/Sub-region, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Oligonucleotides Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type, 2020-2034
13.2.1. Antisense Oligonucleotides
13.2.2. DNA
13.2.3. siRNA
13.2.4. Others (CpG Oligonucleotides)
13.3. Market Value Forecast By Application, 2020-2034
13.3.1. Molecular Biology
13.3.2. Gene Therapy
13.3.3. Drug Development
13.3.4. Diagnostics
13.3.5. Others (Nanotechnology, Research studies etc.)
13.4. Market Value Forecast By End-user, 2020-2034
13.4.1. Hospitals
13.4.2. Pharma & Biopharma Companies
13.4.3. Diagnostic Laboratories
13.4.4. Biotechnology Companies
13.4.5. CROs and CMOs
13.4.6. Others (Academic Research Institutes, etc.)
13.5. Market Value Forecast By Country/Sub-region, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of LATAM
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Oligonucleotides Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type, 2020-2034
14.2.1. Antisense Oligonucleotides
14.2.2. DNA
14.2.3. siRNA
14.2.4. Others (CpG Oligonucleotides)
14.3. Market Value Forecast By Application, 2020-2034
14.3.1. Molecular Biology
14.3.2. Gene Therapy
14.3.3. Drug Development
14.3.4. Diagnostics
14.3.5. Others (Nanotechnology, Research studies etc.)
14.4. Market Value Forecast By End-user, 2020-2034
14.4.1. Hospitals
14.4.2. Pharma & Biopharma Companies
14.4.3. Diagnostic Laboratories
14.4.4. Biotechnology Companies
14.4.5. CROs and CMOs
14.4.6. Others (Academic Research Institutes, etc.)
14.5. Market Value Forecast By Country/Sub-region, 2020-2034
14.5.1. South Africa
14.5.2. GCC Countries
14.5.3. Rest of MEA
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2023)
15.3. Company Profiles
15.3.1. Agilent Technologies
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Ajinomoto Bio-Pharma Services
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. CordenPharma
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Creative Biolabs
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Ella Biotech
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Eurofins Genomics
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Future synthesis
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Integrated DNA Technologies
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Kaneka Eurogentec
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Thermo Fisher Scientific Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Merck
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Microsynth
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Nitto Avecia
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
List of Tables
Table 01: Global Oligonucleotides Market Value (US$ Bn) Forecast, By Type, 2020-2034
Table 02: Global Oligonucleotides Market Value (US$ Bn) Forecast, By Application, 2020-2034
Table 03: Global Oligonucleotides Market Value (US$ Bn) Forecast, By End-user, 2020-2034
Table 04: Global Oligonucleotides Market Value (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Oligonucleotides Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Oligonucleotides Market Value (US$ Bn) Forecast, by Type, 2020-2034
Table 07: North America Oligonucleotides Market Value (US$ Bn) Forecast, by Application, 2020-2034
Table 08: North America Oligonucleotides Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 09: Europe Oligonucleotides Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Oligonucleotides Market Value (US$ Bn) Forecast, by Type, 2020-2034
Table 11: Europe Oligonucleotides Market Value (US$ Bn) Forecast, by Application, 2020-2034
Table 12: Europe Oligonucleotides Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Oligonucleotides Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Oligonucleotides Market Value (US$ Bn) Forecast, by Type, 2020-2034
Table 15: Asia Pacific Oligonucleotides Market Value (US$ Bn) Forecast, by Application, 2020-2034
Table 16: Asia Pacific Oligonucleotides Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 17: Latin America Oligonucleotides Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Oligonucleotides Market Value (US$ Bn) Forecast, by Type, 2020-2034
Table 19: Latin America Oligonucleotides Market Value (US$ Bn) Forecast, by Application, 2020-2034
Table 20: Latin America Oligonucleotides Market Value (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Forecast, by Type, 2020-2034
Table 23: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Forecast, by Application, 2020-2034
Table 24: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Oligonucleotides Market Value (US$ Bn) Forecast, 2020-2034
Figure 02: Global Oligonucleotides Market Value Share, by Type, 2023
Figure 03: Global Oligonucleotides Market Value Share, by Application, 2023
Figure 04: Global Oligonucleotides Market Value Share, by En d-user, 2023
Figure 05: Global Oligonucleotides Market Value Share, By Region, 2023
Figure 06: Global Oligonucleotides Market Value (US$ Bn) Share Analysis, By Type, 2023 and 2034
Figure 07: Global Oligonucleotides Market Share Analysis, By Type, 2023
Figure 08: Global Oligonucleotides Market Share Analysis, By Type, 2034
Figure 09: Global Oligonucleotides Market Attractiveness Analysis, By Type, 2024-2034
Figure 10: Global Oligonucleotides Market Value (US$ Bn), by Antisense Oligonucleotidess, 2020‒2034
Figure 11: Global Oligonucleotides Market Value Share Analysis, by Antisense Oligonucleotidess, 2023 and 2034
Figure 12: Global Oligonucleotides Market Value (US$ Bn), by DNA, 2020‒2034
Figure 13: Global Oligonucleotides Market Value Share Analysis, by DNA, 2023 and 2034
Figure 14: Global Oligonucleotides Market Value (US$ Bn), by siRNA, 2020‒2034
Figure 15: Global Oligonucleotides Market Value Share Analysis, by siRNA, 2023 and 2034
Figure 16: Global Oligonucleotides Market Value (US$ Bn), by Others (CpG Oligonucleotidess) , 2020‒2034
Figure 17: Global Oligonucleotides Market Value Share Analysis, by Others (CpG Oligonucleotidess), 2023 and 2034
Figure 18: Global Oligonucleotides Market Value (US$ Bn) Share Analysis, By Application, 2023 and 2034
Figure 19: Global Oligonucleotides Market Share Analysis, By Application, 2023
Figure 20: Global Oligonucleotides Market Share Analysis, By Application, 2034
Figure 21: Global Oligonucleotides Market Attractiveness Analysis, By Application, 2024-2034
Figure 22: Global Oligonucleotides Market Value (US$ Bn), by Molecular Biology, 2020‒2034
Figure 23: Global Oligonucleotides Market Value Share Analysis, by Molecular Biology, 2023 and 2034
Figure 24: Global Oligonucleotides Market Value (US$ Bn), by Gene Therapy, 2020‒2034
Figure 25: Global Oligonucleotides Market Value Share Analysis, by Genetic Disorders, 2023 and 2034
Figure 26: Global Oligonucleotides Market Value (US$ Bn), by Drug Development, 2020‒2034
Figure 27: Global Oligonucleotides Market Value Share Analysis, by Drug Development, 2023 and 2034
Figure 27: Global Oligonucleotides Market Value (US$ Bn), by Rare Diseases, 2020‒2034
Figure 29: Global Oligonucleotides Market Value Share Analysis, by Diagnostics, 2023 and 2034
Figure 30: Global Oligonucleotides Market Value (US$ Bn), by Others, 2020‒2034
Figure 31: Global Oligonucleotides Market Value Share Analysis, by Others, 2023 and 2034
Figure 32: Global Oligonucleotides Market Value (US$ Bn) Share Analysis, By End-user, 2023 and 2034
Figure 33: Global Oligonucleotides Market Share Analysis, By End-user, 2023
Figure 34: Global Oligonucleotides Market Share Analysis, By End-user, 2034
Figure 35: Global Oligonucleotides Market Attractiveness Analysis, By End-user, 2024-2034
Figure 36: Global Oligonucleotides Market Value (US$ Bn), by Hospitals, 2020‒2034
Figure 37: Global Oligonucleotides Market Value Share Analysis, by Hospitals, 2023 and 2034
Figure 38: Global Oligonucleotides Market Value (US$ Bn), by Pharma & Biopharma Companies, 2020‒2034
Figure 39: Global Oligonucleotides Market Value Share Analysis, by Pharma & Biopharma Companies, 2023 and 2034
Figure 40: Global Oligonucleotides Market Value (US$ Bn), by Diagnostic Laboratories, 2020‒2034
Figure 41: Global Oligonucleotides Market Value Share Analysis, by Diagnostic Laboratories, 2023 and 2034
Figure 42: Global Oligonucleotides Market Value (US$ Bn), by Biotechnology Companies, 2020‒2034
Figure 43: Global Oligonucleotides Market Value Share Analysis, by Biotechnology Companies, 2023 and 2034
Figure 44: Global Oligonucleotides Market Value (US$ Bn), by CROs and CMOs, 2020‒2034
Figure 45: Global Oligonucleotides Market Value Share Analysis, by CROs and CMOs, 2023 and 2034
Figure 46: Global Oligonucleotides Market Value (US$ Bn), Others, 2020‒2034
Figure 47: Global Oligonucleotides Market Value Share Analysis, by Others, 2023 and 2034
Figure 48: Global Oligonucleotides Market Value Share Analysis, by Region, 2023 and 2034
Figure 49: Global Oligonucleotides Market Share Analysis, by Region, 2023
Figure 50: Global Oligonucleotides Market Share Analysis, by Region, 2034
Figure 51: Global Oligonucleotides Market Attractiveness Analysis, by Region, 2023-2034
Figure 52: North America Oligonucleotides Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 53: North America Oligonucleotides Market Value Share Analysis, by Country, 2023 and 2034
Figure 54: North America Oligonucleotides Market Attractiveness Analysis, by Country, 2024-2034
Figure 55: North America Oligonucleotides Market Value (US$ Bn) Share Analysis, by Type, 2023 and 2034
Figure 56: North America Oligonucleotides Market Attractiveness Analysis, by Type, 2024-2034
Figure 57: North America Oligonucleotides Market Value (US$ Bn) Share Analysis, by Application, 2023 and 2034
Figure 58: North America Oligonucleotides Market Attractiveness Analysis, by Application, 2024-2034
Figure 59: North America Oligonucleotides Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 60: North America Oligonucleotides Market Attractiveness Analysis, by End-user, 2024-2034
Figure 61: Europe Oligonucleotides Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 62: Europe Oligonucleotides Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 63: Europe Oligonucleotides Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 64: Europe Oligonucleotides Market Value (US$ Bn) Share Analysis, by Type, 2023 and 2034
Figure 65: Europe Oligonucleotides Market Attractiveness Analysis, by Type, 2024-2034
Figure 66: Europe Oligonucleotides Market Value (US$ Bn) Share Analysis, by Application, 2023 and 2034
Figure 67: Europe Oligonucleotides Market Attractiveness Analysis, by Application, 2024-2034
Figure 68: Europe Oligonucleotides Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 69: Europe Oligonucleotides Market Attractiveness Analysis, by End-user, 2024-2034
Figure 70: Asia Pacific Oligonucleotides Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 71: Asia Pacific Oligonucleotides Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 72: Asia Pacific Oligonucleotides Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 73: Asia Pacific Oligonucleotides Market Value (US$ Bn) Share Analysis, by Type, 2023 and 2034
Figure 74: Asia Pacific Oligonucleotides Market Attractiveness Analysis, by Type, 2024-2034
Figure 75: Asia Pacific Oligonucleotides Market Value (US$ Bn) Share Analysis, by Application, 2023 and 2034
Figure 76: Asia Pacific Oligonucleotides Market Attractiveness Analysis, by Application, 2024-2034
Figure 77: Asia Pacific Oligonucleotides Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 78: Asia Pacific Oligonucleotides Market Attractiveness Analysis, by End-user, 2024-2034
Figure 79: Latin America Oligonucleotides Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 80: Latin America Oligonucleotides Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 81: Latin America Oligonucleotides Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 82: Latin America Oligonucleotides Market Value (US$ Bn) Share Analysis, by Type, 2023 and 2034
Figure 83: Latin America Oligonucleotides Market Attractiveness Analysis, by Type, 2024-2034
Figure 84: Latin America Oligonucleotides Market Value (US$ Bn) Share Analysis, by Application, 2023 and 2034
Figure 85: Latin America Oligonucleotides Market Attractiveness Analysis, by Application, 2024-2034
Figure 86: Latin America Oligonucleotides Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 87: Latin America Oligonucleotides Market Attractiveness Analysis, by End-user, 2024-2034
Figure 88: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 89: Middle East & Africa Oligonucleotides Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 90: Middle East & Africa Oligonucleotides Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 91: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Share Analysis, by Type, 2023 and 2034
Figure 92: Middle East & Africa Oligonucleotides Market Attractiveness Analysis, by Type, 2024-2034
Figure 93: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Share Analysis, by Application, 2023 and 2034
Figure 94: Middle East & Africa Oligonucleotides Market Attractiveness Analysis, by Application, 2024-2034
Figure 95: Middle East & Africa Oligonucleotides Market Value (US$ Bn) Share Analysis, by End-user, 2023 and 2034
Figure 96: Middle East & Africa Oligonucleotides Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Oligonucleotides Market
